To watch the interview with CEO Olav Hellebo which was broadcast on CNBC on the 3oth December 2016, please click here.
To watch the interview with CEO Olav Hellebo which was broadcast on CNBC on the 3oth December 2016, please click here.
In this interview, CFO Michael Hunt explains the core technology of ReNeuron’s business, the stem cell science it is developing, optimising and harnessing to create therapeutic products. He discusses the recently reported early Phase II clinical trial data for its CTX stem cell therapy in stroke and why this has given ReNeuron the confidence to commence a pivotal Phase II/III clinical trial in 2017. Finally, he also discusses expected newsflow resulting from the remainder of ReNeuron’s pipeline – critical limb ischaemia (Phase I) and hRPC or retinitis pigmentosa (Phase I/II).
Please click on link below for the webcast of the Phase II stroke trial & Interim results presentation :
5 December 2016: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce positive data from the Company’s Phase II clinical trial (PISCES II) of its CTX cell therapy candidate for stroke disability.
Published long term Phase I data show evidence of improvements in neurological function sustained out to 24 months and good safety profile.